HK1176548A1 - Pharmaceutical for oral delivery comprising mgbg and methods of treating disease mgbg - Google Patents
Pharmaceutical for oral delivery comprising mgbg and methods of treating disease mgbgInfo
- Publication number
- HK1176548A1 HK1176548A1 HK13103363.8A HK13103363A HK1176548A1 HK 1176548 A1 HK1176548 A1 HK 1176548A1 HK 13103363 A HK13103363 A HK 13103363A HK 1176548 A1 HK1176548 A1 HK 1176548A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mgbg
- pharmaceutical
- methods
- oral delivery
- treating disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22606009P | 2009-07-16 | 2009-07-16 | |
US29009509P | 2009-12-24 | 2009-12-24 | |
PCT/US2010/042253 WO2011009039A2 (en) | 2009-07-16 | 2010-07-16 | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1176548A1 true HK1176548A1 (en) | 2013-08-02 |
Family
ID=43450234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13103363.8A HK1176548A1 (en) | 2009-07-16 | 2013-03-18 | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease mgbg |
Country Status (12)
Country | Link |
---|---|
US (4) | US8258186B2 (de) |
EP (2) | EP3473247A1 (de) |
JP (4) | JP6112449B2 (de) |
CN (2) | CN104997762B (de) |
AU (2) | AU2010273277B2 (de) |
BR (1) | BR112012000862A8 (de) |
CA (1) | CA2768018C (de) |
DK (1) | DK2453886T3 (de) |
ES (1) | ES2715173T3 (de) |
HK (1) | HK1176548A1 (de) |
NZ (3) | NZ715686A (de) |
WO (1) | WO2011009039A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2121586T3 (en) | 2007-03-09 | 2017-06-19 | Pathologica Llc | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS |
NZ715686A (en) | 2009-07-16 | 2017-08-25 | Pathologica Llc | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
US9675566B2 (en) * | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
PT2665471T (pt) | 2011-01-19 | 2018-03-21 | Pathologica Llc | Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg |
WO2013083813A2 (en) * | 2011-12-07 | 2013-06-13 | Universität Zürich | Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis |
WO2014062552A1 (en) * | 2012-10-15 | 2014-04-24 | Nestec Sa | Methods for maintaining eye health and ameliorating opthalmic maladies in animals |
ES2859553T3 (es) * | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
EP3785706B1 (de) | 2016-03-25 | 2023-06-07 | Aminex Therapeutics, Inc. | Bioverfügbare polyamine |
WO2018027149A1 (en) * | 2016-08-04 | 2018-02-08 | University Of Miami | Methods of treating alport syndrome |
JP6840386B2 (ja) * | 2017-04-26 | 2021-03-10 | 学校法人 関西大学 | 細胞足場材料製造用組成物ならびに細胞足場材料およびその製造方法 |
CA3193185A1 (en) | 2020-09-30 | 2022-04-07 | Mark R. Burns | Combination drug substance of polyamine transport inhibitor and dfmo |
WO2024155777A2 (en) * | 2023-01-19 | 2024-07-25 | Dare Bioscience, Inc. | Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis |
WO2024158951A2 (en) * | 2023-01-25 | 2024-08-02 | Dare Bioscience, Inc. | Compositions and methods for treating dysmenorrhea |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4201788A (en) * | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
US5614557A (en) * | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
JP3470901B2 (ja) | 1996-09-13 | 2003-11-25 | ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイテッド | Elf5A生合成の抑制方法 |
AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
AU758570B2 (en) | 1997-07-15 | 2003-03-27 | Mediquest Therapeutics, Inc. | Novel polyamine analogues as therapeutic and diagnostic agents |
US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
US7087648B1 (en) * | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
US6169115B1 (en) * | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
EP1698629A3 (de) | 1999-04-30 | 2006-11-29 | Cellgate, Inc. | Polyamine und ihre therapeutische Verwendung |
US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
EP1337504A4 (de) | 2000-11-08 | 2005-10-05 | Cellgate Inc | Neue polyaminanalogon-aminosäure-konjugate zur verwendung als krebsmittel |
US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
CA2433807C (en) | 2001-01-08 | 2012-04-24 | Oridigm Corporation | Hydrophobic polyamine analogs and methods for their use |
WO2003013245A1 (en) | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
EP1425380A4 (de) | 2001-08-15 | 2004-12-22 | Univ California | Aus mantelhistiozyten im mantelzellymphom isoliertes retrovirus |
US7211602B2 (en) | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
EP1613263A4 (de) | 2003-01-31 | 2007-11-28 | Pathologica Llc | Überwachung und behandlung von amyotropher lateralsklerose |
US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
US20050113455A1 (en) | 2003-10-22 | 2005-05-26 | Bergeron Raymond J.Jr. | Method and composition for amelioration of pain |
AU2004319105A1 (en) | 2004-03-29 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
WO2005107801A2 (en) | 2004-04-29 | 2005-11-17 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies |
EP1912635B1 (de) | 2005-07-29 | 2014-03-05 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Verwendung von chk2-kinasehemmern zur krebsbehandlung |
WO2007035957A2 (en) | 2005-09-23 | 2007-03-29 | Pathologica, Llc. | Methods for treating viral infections using polyamine analogs |
WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
CN101511921A (zh) * | 2006-07-28 | 2009-08-19 | 埃克阿泰克有限责任公司 | 具有聚氨酯底漆的车窗面板 |
US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
DK2121586T3 (en) | 2007-03-09 | 2017-06-19 | Pathologica Llc | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS |
WO2008112251A1 (en) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Cyclopropyl-containing polyamine analogs as disease therapies |
WO2009018368A1 (en) * | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
NZ715686A (en) | 2009-07-16 | 2017-08-25 | Pathologica Llc | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
EP2283830A1 (de) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Wässriger magensaftresistenter Kapselüberzug |
PT2665471T (pt) | 2011-01-19 | 2018-03-21 | Pathologica Llc | Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg |
ES2859553T3 (es) | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
-
2010
- 2010-07-16 NZ NZ715686A patent/NZ715686A/en not_active IP Right Cessation
- 2010-07-16 AU AU2010273277A patent/AU2010273277B2/en not_active Ceased
- 2010-07-16 ES ES10800602T patent/ES2715173T3/es active Active
- 2010-07-16 CN CN201510274080.4A patent/CN104997762B/zh not_active Expired - Fee Related
- 2010-07-16 CA CA2768018A patent/CA2768018C/en active Active
- 2010-07-16 WO PCT/US2010/042253 patent/WO2011009039A2/en active Application Filing
- 2010-07-16 EP EP18210165.9A patent/EP3473247A1/de not_active Ceased
- 2010-07-16 NZ NZ597488A patent/NZ597488A/en not_active IP Right Cessation
- 2010-07-16 JP JP2012520810A patent/JP6112449B2/ja active Active
- 2010-07-16 US US12/837,753 patent/US8258186B2/en active Active
- 2010-07-16 EP EP10800602.4A patent/EP2453886B1/de active Active
- 2010-07-16 DK DK10800602.4T patent/DK2453886T3/en active
- 2010-07-16 CN CN201080041853.XA patent/CN102686222B/zh not_active Expired - Fee Related
- 2010-07-16 BR BR112012000862A patent/BR112012000862A8/pt not_active Application Discontinuation
- 2010-07-16 NZ NZ628513A patent/NZ628513A/en not_active IP Right Cessation
-
2012
- 2012-07-24 US US13/556,948 patent/US8609734B2/en active Active
-
2013
- 2013-03-18 HK HK13103363.8A patent/HK1176548A1/xx not_active IP Right Cessation
- 2013-10-25 US US14/063,541 patent/US9616035B2/en active Active
-
2015
- 2015-09-11 JP JP2015180110A patent/JP2016065045A/ja active Pending
-
2016
- 2016-12-01 AU AU2016266049A patent/AU2016266049B2/en not_active Ceased
-
2017
- 2017-02-23 US US15/441,122 patent/US20170290788A1/en not_active Abandoned
-
2018
- 2018-03-06 JP JP2018040226A patent/JP6883930B2/ja active Active
-
2019
- 2019-11-26 JP JP2019213582A patent/JP2020063258A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1176548A1 (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease mgbg | |
IL276157A (en) | Pharmaceutical preparations and methods for transferring them related to them | |
HUS1600057I1 (hu) | Kezelési eljárások ammónia-megkötõ hatóanyag alkalmazásával | |
EP2515992A4 (de) | Schluckbare wirkstofffreisetzungsvorrichtung und verfahren zur wirkstofffreisetzung | |
LT2303330T (lt) | Farmacinės kompozicijos, skirtos parkinsono ligai gydyti | |
IL216668A0 (en) | Pharmaceutical composition and treatment method for emergrncy contraception | |
EP2514387A4 (de) | Ultraschall-arzneiverabreichungssystem zur zahnärztlichen verwendung und ultraschall-arzneiverabreichungsverfahren zur zahnärztlichen verwendung | |
EP2448406A4 (de) | Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür | |
IL217777A (en) | A peptide for the preparation of pain medication | |
EP2379079A4 (de) | Pharmazeutische formulierungen mit voriconazol und herstellungsverfahren dafür | |
ZA201203281B (en) | Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals | |
EP2271352A4 (de) | Zusammensetzungen und verfahren zur behandlung von neoplastischen erkrankungen | |
HK1183228A1 (zh) | 口服藥物治療方法和組合物 | |
GB201108964D0 (en) | Medicament and method of diagnosis | |
GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
IL217073A0 (en) | Methods and products for treatment of diseases | |
HRP20181877T1 (hr) | Postupci za liječenje lijekovima koji uklanjaju amonijak | |
EP2408511A4 (de) | Feststoffverabreichungsvorrichtung sowie formulierungen und anwendungen dafür | |
EP2517704A4 (de) | Pharmazeutische zusammensetzungen zur behandlung von morbus parkinson und zubereitungsverfahren dafür | |
EP2419085A4 (de) | Verbesserte vorrichtungen für orale arzneimittel und arzneiformen | |
EP2432322A4 (de) | Optimale zusammensetzungen und verfahren zur behandlung von oralen erkrankungen und schmerzen | |
GB0705001D0 (en) | Composition and method for treatment of drug dependence and disease | |
SI2330892T1 (sl) | Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak | |
SI2315580T1 (sl) | Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta | |
GB0803515D0 (en) | Medicament and method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230716 |